Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Gross Margin (2016 - 2023)

Perspective Therapeutics' Gross Margin history spans 14 years, with the latest figure at 0.8% for Q4 2023.

  • For Q4 2023, Gross Margin changed N/A year-over-year to 0.8%; the TTM value through Dec 2023 reached 100.0%, up 4080.0%, while the annual FY2023 figure was 100.0%, N/A changed from the prior year.
  • Gross Margin for Q4 2023 was 0.8% at Perspective Therapeutics, down from 24.55% in the prior quarter.
  • Across five years, Gross Margin topped out at 94.49% in Q2 2022 and bottomed at 0.8% in Q4 2023.
  • The 5-year median for Gross Margin is 46.99% (2020), against an average of 43.43%.
  • The largest annual shift saw Gross Margin soared 4482bps in 2022 before it tumbled -7796bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 50.36% in 2019, then dropped by -2bps to 49.47% in 2020, then decreased by -12bps to 43.32% in 2021, then tumbled by -44bps to 24.11% in 2022, then crashed by -97bps to 0.8% in 2023.
  • Per Business Quant, the three most recent readings for CATX's Gross Margin are 0.8% (Q4 2023), 24.55% (Q3 2023), and 16.53% (Q2 2023).